Ampel BioSolutions is a Charlottesville-based company specializing in personalized precision medicine for autoimmune inflammatory diseases. Their innovative genomic platform, AGP, supports genomic blood and biopsy tests to evaluate disease status, identify cells and pathways, and predict flares and drug targets. With a focus on RNA analytics and predictive AI, Ampel offers dynamic disease management solutions for conditions such as lupus, dermatology, nephrology, cardiology, fibromyalgia, and infections.
Founded by internationally recognized scientists and successful entrepreneurs, Amrie Grammer and Peter Lipsky, Ampel BioSolutions has gained recognition for its groundbreaking research and impact in the field of precision medicine. With 20 pharma customers validating their technology and a product pipeline that includes LuGENE, DermaGENE, and WellGENE, Ampel is at the forefront of developing innovative solutions for personalized care. Their commitment to reducing uncertainty in clinical care through genomic data and analytics sets them apart in the industry.
Generated from the website